Biotie's Annual Report 2009 and Corporate Governance Statement have been published

(Thomson Reuters ONE) -


BIOTIE THERAPIES CORP.     STOCK EXCHANGE ANNOUNCEMENT 15 March 2010 at 1 p.m.
Biotie's Annual Report 2009 and Corporate Governance Statement have been
published

Biotie Therapies Corp.'s Annual Report 2009 and Corporate Governance Statement
have been published as attached to this stock exchange release and on the
company website at www.biotie.com.

The Annual Report including the Financial Statements and the report from the
Board of Directors has been published in Finnish and English.

The printed version of the Annual Report can be ordered at
http://www.biotie.com/In_English/Investors/Financial_Information/Annual_Reports_
2004-2009
or from the company, telephone +358 2 274 8900, e-mail virve.nurmi(at)biotie.com or
address Tykistökatu 6, 20520 Turku, Finland.

Turku, March 15, 2010

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Virve Nurmi, Investor Relations Manager
tel. +358 2 274 8900, e-mail: virve.nurmi(at)biotie.com



Distribution:
NASDAQ OMX Helsinki Ltd
Main Media


Biotie Therapies Corp.
Biotie is a drug discovery and development company focused on central nervous
system and inflammatory diseases. It has a broad range of innovative small
molecule and biological drug candidates at different stages of clinical and
pre-clinical development. Biotie's products address diseases with high unmet
medical need and significant market potential, including addiction and psychotic
disorders, rheumatoid arthritis, psoriasis and chronic obstructive pulmonary
disease (COPD). The most advanced product, nalmefene for alcohol dependence, is
currently in phase III clinical development by licensing partner H. Lundbeck
A/S.

The commercial value of the pipeline has been demonstrated through existing

alliances with top-tier global pharmaceutical companies such as Lundbeck, Roche
and Pfizer. Biotie has operations in Turku, Finland and Radebeul, Germany.

Biotie shares are listed on NASDAQ OMX Helsinki Ltd.

For more information, please refer to www.biotie.com


[HUG#1393883]





Corporate Governance Statement : http://hugin.info/132030/R/1393883/350912.pdf
Annual Report 2009: http://hugin.info/132030/R/1393883/350911.pdf

Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 15.03.2010 - 12:01 Uhr
Sprache: Deutsch
News-ID 17495
Anzahl Zeichen: 0

contact information:
Town:

Turku

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 247 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Biotie's Annual Report 2009 and Corporate Governance Statement have been published"
steht unter der journalistisch-redaktionellen Verantwortung von

Biotie Therapies Oyj (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Biotie Announces Start of Clinical Study With Nepicastat (SYN117) in Cocaine Dep ...

TURKU, FINLAND -- (Marketwired) -- 05/10/13 -- BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 10 May 2013 at 9.00 a.m.Biotie Therapies today announced the start of a Phase 2 clinical study evaluating nepicastat (SYN117) in cocaine dependence. The Nat ...

Biotie: Selincro Launched in the United Kingdom ...

TURKU, FINLAND -- (Marketwired) -- 05/06/13 -- Biotie today announced that its partner H.Lundbeck A/S (Lundbeck) has launched Selincro in the United Kingdom. According to the terms of the license agreement between Biotie and Lundbeck for Selincro, B ...

Biotie: Selincro Launched in First European Markets ...

TURKU, FINLAND -- (Marketwired) -- 04/22/13 -- BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 22 April 2013 at 9:00 a.m.Biotie today announced that its partner H.Lundbeck A/S (Lundbeck) has started launching Selincro™ in the first European markets, ...

Alle Meldungen von Biotie Therapies Oyj